Given the presence of a substantial high-grade urothelial carcinoma component with small cell neuroendocrine differentiation, interpretation of immunotherapy benefit should incorporate evidence from UC populations, where PD-1/PD-L1 blockade has demonstrated proven survival benefit (13). Here, CD274 is linked to urothelial carcinoma.